Trial Profile
A phase II trial of glembatumumab vedotin (CDX-011) for the treatment of paediatric sarcoma
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 20 Apr 2018
Price :
$35
*
At a glance
- Drugs Glembatumumab vedotin (Primary)
- Indications Sarcoma
- Focus Therapeutic Use
- 16 Apr 2018 According to a Celldex Therapeutics media release, status changed from not yet recruiting to discontinued, because based on the data from METRIC study, company has decided to discontinue the glembatumumab vedotin program across all indications.
- 08 Apr 2015 New trial record